OPEN AI founder Sam Altman Invest 180 Million Dollars to Anti-aging Star up

In the pass decades days, the Open AI and the amazing founder behind AI application both captured attention world widely. But recently, as MIT Technology Review reported, the OpenAI CEO Sam Altman has turned out to be the investor that paid $180 million to get biotech startup Retro Biosciences off the ground. 

Altman anti-aging theory shaping and investment 

Motivated by his own idea of three biggest positive humans affairs of AI, energy, and anti-aging biotech, the investment to anti-aging area should date back to eight years ago. Altman told Tech Review that he became fascinated by “young blood” research, in which old mice have their fluids swapped out with fresher juice in 2015. It was through this burgeoning interest, and a conversation about a 2020 plasma mouse study, that he reportedly first expressed a desire to pursue anti-aging work. From those initial motivation, a business partnership blossomed. What’s more, Altman's have highlighted that his anti-aging regimen includes trying to eat healthy, exercise, and sleep enough. He basically just took all his liquid net worth and put it into these two companies one of which named Retro Biosciences.
The investment by Sam Altman in this life-extension startup is a positive signal for the anti-aging business development. It shows that there is a growing interest and support for anti-aging research and development, and it could pave the way for other investors and companies to enter the field. On the other hand, that is a significant milestone in the anti-aging industry. It highlights the potential of anti-aging technologies to improve human lifespan and quality of life.

Retro Bio anti-aging theory

Based on the MIT Technology Review, Retro Biosciences aims to address the underlying causes of aging by developing therapies that target cellular and molecular mechanisms. It uses cutting-edge technologies such as gene editing, stem cell therapy, and artificial intelligence to develop interventions that can slow down or even reverse the aging process. And it publicly launched in April 2022, under the leadership of CEO Joe Betts-LaCroix, another Y Combinator alum and health startup entrepreneur. At launch, the company had secured funding for an ambitious mission of adding 10 years to the healthy human lifespan. It announced it had raised $180 million in its initial funding round, however, which apparently came in the form of a 2021 confidential check from Altman.

Bontac stands on anti-aging points

Bontac anti-aging theory originated from David Sinclair who is a professor in the Department of Genetics and co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. Technically, he featured the effects of anti-aging for NMN (nicotinamide mononucleotide) from the perspectives of theory and experiment and Bontac have played a role of NMN industrialization practitioners.
NMN is a molecule that has gained attention for its potential anti-aging properties. It is a precursor to NAD+ (nicotinamide adenine dinucleotide), which is an essential coenzyme involved in many cellular processes, including energy metabolism and DNA repair. NMN's mechanism of action in anti-aging appears to be related to its ability to increase NAD+ levels and activate sirtuins, leading to improvements in cellular processes that decline with age.

Reference: 
https://sinclair.hms.harvard.edu/people/david-sinclair
https://www.technologyreview.com/2023/03/08/1069523/sam-altman-investment-180-million-retro-biosciences-longevity-death/